Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Spellman

Morehead City, NC Medical Doctor

NPI 1972761823 CMS profile 1307502

4218-M Arendell Street, Morehead City, NC 28557

Open in the dashboard

General payments

$4,371

54 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Spellman of Morehead City, NC is reported in the CMS Open Payments database as having received $4,371 across 54 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $722 5
2023 General $810 8
2022 General $1,299 22
2021 General $271 2
2020 General $1,252 16
2019 General $17 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Spellman
  • North Carolina median
  • Middle half of North Carolina
  • National median

In program year 2025, general payments to John Spellman were reported at $722. Among 34,409 North Carolina profiles paid that year, the median was $159 and the middle half received between $47 and $573.

Show as a table
Year John Spellman North Carolina median Middle half National median
2019 $17 $167 $52–$671 $163
2020 $1,252 $110 $33–$382 $114
2021 $271 $125 $36–$459 $132
2022 $1,299 $145 $42–$538 $149
2023 $810 $153 $45–$549 $160
2024 $0 $156 $45–$572 $164
2025 $722 $159 $47–$573 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $2,192 36 payments
  2. Stryker Corporation $1,529 12 payments
  3. SouthTech Orthopedics $517 1 payment
  4. Medacta USA, Inc. $49 1 payment
  5. SI-BONE, Inc. $27 1 payment
  6. Vertex Pharmaceuticals Incorporated $21 1 payment
  7. Eagle Pharmaceuticals, Inc. $19 1 payment
  8. Zimmer Biomet Holdings, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,116 14 payments
  2. Food and Beverage $1,255 40 payments
Products named General payments · program years 2019–2025
  1. AEQUALIS PERFORM $358 1 payment
  2. INSPACE $223 3 payments
  3. BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION $193 2 payments
  4. SALVATION $188 2 payments
  5. AEQUALIS ASCEND FLEX $151 1 payment
  6. ARTHROPLASTY IMPLANTS SHOULDER ARTHROPLASTY & FRACTURE ECLIPSE $117 1 payment
  7. HIPCHECK $74 1 payment
  8. AEQUALIS PERFORM REVERSED $71 1 payment
  9. MAKO $68 1 payment
  10. GMK SPHERE $49 1 payment
  11. Other $73 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

87

Median for Orthopedic Surgery: 203

Drug cost

$867

Median for Orthopedic Surgery: $1,433

Branded share of claims

18.4%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 40 $616
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $177
Meloxicam Generic 18 $51
Cephalexin Generic 13 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 80 billing codes

Paid by Medicare

$244,617

Of which drugs: $27,349

Medicare patients

468

Average age 73

Services billed

6,807

284 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 24%
Diabetes 21%
Ischemic heart disease 19%
Osteoporosis 18%
Chronic kidney disease 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 36 2,258 $15,528
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 22 69 $6,689
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 214 1,830 $1,382

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

54 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record